A2A Pharma
top of page
Search
Recent Posts
See AllBiomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers, announced the closing of
4600
A2A Pharmaceuticals Inc. Today Announced a Multi-target Co-development Agreement With Daewoong Pharmaceutical for AI-enhanced Oncology Drug Discovery. LEARN MORE
2340
A2A Pharmaceuticals Appoints Dr. Sotirios Stergiopoulos Chief Executive Officer LEARN MORE
1550
bottom of page